Tabla 1: Características demográficas

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hombre**  **n: 47 (32,6%)** | **Mujer**  **n: 97**  **(67,4%** | **relacion H:M** |
| Edad meses mediana (p25 - p75) | 21 (7-28) | 34 (19,5-78) |  |
| Edad<1 año | 15 (51,7%) | 14 (48,3%) | 1.07:1 |
| Edad 1 a 2 años | 25 (37,3%) | 42 (62,7%) | 1:1,68 |
| Edad >2 a 5 años | 4 (20%) | 16 (80%) | 1:4 |
| Edad > 5 años | 2 (7,4%) | 25 (92,6%) | 1:12,5 |
|  |  |  |  |
| % de Infección por *Escherichia coli* | 51% (24/47) | 82% (80/97) |  |
| Antecedentes de malformaciones urinarias | 25% (12/47) | 11,3% (11/97) |  |
| Antecedentes de ITU previas | 49% (19/47) | 26,8% (26/97) |  |

**Tabla 2: Presencia de síntomas de acuerdo a los grupos de edad.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Grupos edad | | | |
| < 1año | >1-2 años | >2-5 años | >5 años |
| Fiebre | 75.86% | 83,5% | 80% | 77,7% |
| Vómito | 27,5% | 29,8% | 40% | 40,% |
| Irritabilidad | 41,3% | 35,8% | 20% | 3,7% |
| Diarrea | 17,2% | 19,4% | 15% | 3,7% |
| Dolor abdominal | 6,89% | 23,8% | 35% | 59,2% |
| Sintomas respiratorio | 27,5% | 41.7% | 5% | 11,1% |
| Disuria | 0% | 17,9% | 25% | 48,1% |
| Urgencia | 0% | 21,42% | 5% | 11,1% |
| Otras infecciones | 13,8% | 16,4% | 0% | 3,7% |
| TOTAL | 29 | 67 | 20 | 27 |

**TABLA 3 Aislamiento en el urocultivo**

|  |  |  |
| --- | --- | --- |
|  | **Frecuencia** | **%** |
| *Escherichia coli* | 104 | 72,7 |
| *Klebsiella pneumoniae* | 12 | 8,3 |
| *Klebsiella oxytoca* | 1 | 0,7 |
| *Proteus mirabilis* | 9 | 6,3 |
| *Pseudomonas aeruginosa* | 6 | 4,2 |
| *Staphylococcus aureus* | 1 | 0,7 |
| *Enterobacter aerogenes* | 2 | 1,4 |
| *Enterococcus faecalis* | 5 | 3,5 |
| *Entercoccus spp.* | 1 | 0,7 |
| *Raoultella planticola* | 1 | 0,7 |
| *Morganella morganii* | 1 | 0,7 |
| *Candida albicans* | 1 | 0,7 |
| Total | 144 | 100 |

**Tabla 4: Resistencia antibiótica por aislamiento**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Especie (n) | AMK | AMP | AMP-SUL | PIP-TAZ | CEF | CAZ | IMI | CIP | NIT | NAL | TMS |
| *Escherichia coli (101)* | 4 (4%) | 64 (63,3%) | 47 (47,6%) | 4 (4%) | 3 (3%) | 4 (3,8%) | 2 (2%) | 7 (7%)) | 18 (18%) | 21 (21,4%) | 43 (42,6%) |
| *Klebsiella pneumoniae (12)* | 1 (8,4%) | 12 (100%) | 2 (17%) | 2 (16,7%) | 1 (8,4%) | 1 (8,3%) | 0 (0%) | 0 (0%) | 3 (25%) | 0 (0%) | 0 (0%) |
| *Proteus mirabilis(9)* | 0 (0%) | 9 (100%) | 1 (11,2%) | 1 (11,2%) | 0 (0%) | 0 (0%) | 1 (11,2%) | 0 (0%) | 9 (100%) | 0 (0%) | 0 (0%) |
| *Pseudomonas aeruginosa (6)* | 0 (0% ) | 9 (100%) | 4 (66,6%) | 1 (16,7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (100%) | 0 (0%) | NA |

Amk: amikacina; Amp: ampicilina; Amp-sulb: ampicilina sulbactam; pip-taz: piperacilina-tazobactam, cef: cefepime; CAZ: ceftazidime; ciprofl: ciprofloxacina; Nitrof: nitrofurantoina; NAL: acido nalidixico, TMS: trimetropin-sulfametoxazole, NA: no aplica, IMI: imipenem